Zero Candida Begins Prototype Production of AI-Enabled Therapeutic Device ZC-001

Oct 21, 2025
Zero Candida Technologies has completed the design freeze and started prototype production of its AI-driven therapeutic device ZC-001 for treating Vulvo-Vaginal Candidiasis, with 50 units expected by early 2026.

Zero Candida Technologies, Inc. has completed the design freeze and started prototype production of its ZC-001 therapeutic device, announced in a press release. The company will produce 50 prototype units, expected to be completed by the first quarter of 2026.

The ZC-001 device integrates blue light therapy, targeted drug delivery, and wireless diagnostics to provide personalized treatment for Vulvo-Vaginal Candidiasis (VVC). The design freeze finalizes specifications for both the device and its SMART docking and charging case.

Key features include a docking system for automatic alignment and sterilization, wireless connectivity for encrypted data transfer, light indicators for user feedback, and medical-grade materials for comfort and biocompatibility. The device is designed for at-home use with real-time data transmission to enable physician monitoring and AI-driven analytics.

According to the company, the modular design of ZC-001 will support scalable manufacturing and potential adaptation for other gynecologic applications.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.